UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Targeting BRAF‐Mutant Non‐Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy

The oncologist (Dayton, Ohio), 2017-07, Vol.22 (7), p.786-796

2017

Volltextzugriff (PDF)

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

The lancet oncology, 2021-07, Vol.22 (7), p.959-969

2021

Volltextzugriff (PDF)

A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer

Clinical cancer research, 2020-02, Vol.26 (4), p.837-845

2020

Volltextzugriff (PDF)

Emerging molecular biomarkers-blood-based strategies to detect and monitor cancer

Nature reviews. Clinical oncology, 2011-03, Vol.8 (3), p.142-150

2011

Volltextzugriff (PDF)

Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma

Neuro-oncology (Charlottesville, Va.), 2017-01, Vol.19 (1), p.i1-i24

2017

Volltextzugriff (PDF)

HER2 in Non-Small Cell Lung Cancer: A Review of Emerging Therapies

Cancers, 2022-08, Vol.14 (17), p.4155

2022

Volltextzugriff (PDF)

Targeted Therapy for Brain Metastases in EGFR-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer

Journal of thoracic oncology, 2015-09, Vol.10 (9), p.1268-1278

2015

Volltextzugriff (PDF)

Reproductive Factors, Hormone Use, and Risk for Lung Cancer in Postmenopausal Women, the Nurses' Health Study

Cancer epidemiology, biomarkers & prevention, 2010-10, Vol.19 (10), p.2525-2533

2010

Volltextzugriff (PDF)

Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patients

Cancer medicine (Malden, MA), 2022-11, Vol.11 (22), p.4104-4111

2022

Volltextzugriff (PDF)

Estrogen signaling in lung cancer: an opportunity for novel therapy

Cancers, 2012-09, Vol.4 (4), p.969-988

2012

Volltextzugriff (PDF)

Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial

The lancet oncology, 2016-07, Vol.17 (7), p.984-993

2016

Volltextzugriff (PDF)

Clinical Outcomes With Dabrafenib Plus Trametinib in a Clinical Trial Versus Real-World Standard of Care in Patients With BRAF-Mutated Advanced NSCLC

JTO clinical and research reports, 2022-05, Vol.3 (5), p.100324-100324, Article 100324

2022

Volltextzugriff (PDF)

Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers

Clinical cancer research, 2019-01, Vol.25 (1), p.64-72

2019

Volltextzugriff (PDF)

Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

The lancet. Diabetes & endocrinology, 2021-08, Vol.9 (8), p.491-501

2021

Volltextzugriff (PDF)

Prognostic Value of Early Fluorodeoxyglucose-Positron Emission Tomography Response Imaging and Peripheral Immunologic Biomarkers: Substudy of a Phase II Trial of Risk-Adaptive Chemoradiation for Unresectable Non-Small Cell Lung Cancer

Advances in radiation oncology, 2022-03, Vol.7 (2), p.100857, Article 100857

2022

Volltextzugriff (PDF)

Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN

Clinical cancer research, 2017-05, Vol.23 (10), p.2442-2450

2017

Volltextzugriff (PDF)

New Immuno-oncology Targets and Resistance Mechanisms

Current treatment options in oncology, 2022-09, Vol.23 (9), p.1201-1218

2022

Volltextzugriff (PDF)

Immuno-oncology Clinical Trial Design: Limitations, Challenges, and Opportunities

Clinical cancer research, 2017-09, Vol.23 (17), p.4992-5002

2017

Volltextzugriff (PDF)

Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication

Journal of thoracic oncology, 2015-10, Vol.10 (10), p.e97-e99

2015

Volltextzugriff (PDF)

Non‐steroidal anti‐inflammatory drugs and cancer risk in women: Results from the Women's Health Initiative

International journal of cancer, 2014-10, Vol.135 (8), p.1869-1883

2014

Volltextzugriff (PDF)

Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2019-02, Vol.128, p.74-90

2019

Volltextzugriff (PDF)

Pralsetinib in patients with RET fusion–positive non-small cell lung cancer: A plain language summary of the ARROW study

Future oncology (London, England), 2024-02, Vol.20 (6), p.297-306

2024

Volltextzugriff (PDF)

High End-of-Life Health Care Utilization in a Contemporary Cohort of Head and Neck Cancer Patients Treated with Immune Checkpoint Inhibitors

Journal of palliative medicine, 2022-04, Vol.25 (4), p.614

2022

Volltextzugriff (PDF)

Duration of Targeted Therapy in Patients With Advanced Non–small-cell Lung Cancer Identified by Circulating Tumor DNA Analysis

Clinical lung cancer, 2020-11, Vol.21 (6), p.545-552.e1

2020

Volltextzugriff (PDF)

1 – 25 von 160

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(154)
Mit Volltextzugriff
(143)

Publikationsform

Artikel
(159)
Berichte
(1)

Sprache

Englisch
(158)
Japanisch
(15)

Erscheinungsjahr

n.n

Thema

Science & Technology
(85)
Life Sciences & Biomedicine
(83)
Oncology
(49)
Humans
(47)
Female
(30)
Middle Aged
(24)
Aged
(23)
Lung Neoplasms - Drug Therapy
(21)
Male
(21)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(19)
Lung Cancer
(15)
Lung Neoplasms - Genetics
(15)
Mutation
(15)
Adult
(14)
Carcinoma, Non-Small-Cell Lung - Genetics
(14)
Lung Neoplasms - Pathology
(13)
Metastasis
(13)
Patients
(13)
Carcinoma, Non-Small-Cell Lung - Pathology
(12)
Agriculture
(11)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

Targeting BRAF‐Mutant Non‐Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy

Dabrafenib plus trametinib in patients with previously treated BRAFV600E -mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial

Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study

A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer

Emerging molecular biomarkers-blood-based strategies to detect and monitor cancer

Systemic therapy of brain metastases: non-small cell lung cancer, breast cancer, and melanoma

HER2 in Non-Small Cell Lung Cancer: A Review of Emerging Therapies

Targeted Therapy for Brain Metastases in EGFR-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer

Reproductive Factors, Hormone Use, and Risk for Lung Cancer in Postmenopausal Women, the Nurses' Health Study

Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patients

Estrogen signaling in lung cancer: an opportunity for novel therapy

Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial

Clinical Outcomes With Dabrafenib Plus Trametinib in a Clinical Trial Versus Real-World Standard of Care in Patients With BRAF-Mutated Advanced NSCLC

Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers

Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study

Prognostic Value of Early Fluorodeoxyglucose-Positron Emission Tomography Response Imaging and Peripheral Immunologic Biomarkers: Substudy of a Phase II Trial of Risk-Adaptive Chemoradiation for Unresectable Non-Small Cell Lung Cancer

Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN

New Immuno-oncology Targets and Resistance Mechanisms

Immuno-oncology Clinical Trial Design: Limitations, Challenges, and Opportunities

Durable Response to Tyrosine Kinase Inhibitor Therapy in a Lung Cancer Patient Harboring Epidermal Growth Factor Receptor Tandem Kinase Domain Duplication

Non‐steroidal anti‐inflammatory drugs and cancer risk in women: Results from the Women's Health Initiative

Real-world treatment patterns and survival of patients with BRAF V600-mutated metastatic non-small cell lung cancer

Pralsetinib in patients with RET fusion–positive non-small cell lung cancer: A plain language summary of the ARROW study

High End-of-Life Health Care Utilization in a Contemporary Cohort of Head and Neck Cancer Patients Treated with Immune Checkpoint Inhibitors

Duration of Targeted Therapy in Patients With Advanced Non–small-cell Lung Cancer Identified by Circulating Tumor DNA Analysis

Suchergebnisse filtern